Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Seung-Jung | - |
dc.contributor.author | Ahn, Jung-Min | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Park, Duk-Woo | - |
dc.contributor.author | Yun, Sung-Cheol | - |
dc.contributor.author | Lee, Jong-Young | - |
dc.contributor.author | Kang, Soo-Jin | - |
dc.contributor.author | Lee, Seung-Whan | - |
dc.contributor.author | Lee, Cheol Whan | - |
dc.contributor.author | Park, Seong-Wook | - |
dc.contributor.author | Choo, Suk Jung | - |
dc.contributor.author | Chung, Cheol Hyun | - |
dc.contributor.author | Lee, Jae Won | - |
dc.contributor.author | Cohen, David J. | - |
dc.contributor.author | Yeung, Alan C. | - |
dc.contributor.author | Hur, Seung Ho | - |
dc.contributor.author | Seung, Ki Bae | - |
dc.contributor.author | Ahn, Tae Hoon | - |
dc.contributor.author | Kwon, Hyuck Moon | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Lee, Bong-Ki | - |
dc.contributor.author | Tresukosol, Damras | - |
dc.contributor.author | Fu, Guo Sheng | - |
dc.contributor.author | Ong, Tiong Kiam | - |
dc.date.accessioned | 2021-09-04T18:02:58Z | - |
dc.date.available | 2021-09-04T18:02:58Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-03-26 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94087 | - |
dc.description.abstract | BACKGROUND Most trials comparing percutaneous coronary intervention (PCI) with coronary-artery bypass grafting (CABG) have not made use of second-generation drug-eluting stents. METHODS We conducted a randomized noninferiority trial at 27 centers in East Asia. We planned to randomly assign 1776 patients with multivessel coronary artery disease to PCI with everolimus-eluting stents or to CABG. The primary end point was a composite of death, myocardial infarction, or target-vessel revascularization at 2 years after randomization. Event rates during longer-term follow-up were also compared between groups. RESULTS After the enrollment of 880 patients (438 patients randomly assigned to the PCI group and 442 randomly assigned to the CABG group), the study was terminated early owing to slow enrollment. At 2 years, the primary end point had occurred in 11.0% of the patients in the PCI group and in 7.9% of those in the CABG group (absolute risk difference, 3.1 percentage points; 95% confidence interval [CI], -0.8 to 6.9; P = 0.32 for noninferiority). At longer-term follow-up (median, 4.6 years), the primary end point had occurred in 15.3% of the patients in the PCI group and in 10.6% of those in the CABG group (hazard ratio, 1.47; 95% CI, 1.01 to 2.13; P = 0.04). No significant differences were seen between the two groups in the occurrence of a composite safety end point of death, myocardial infarction, or stroke. However, the rates of any repeat revascularization and spontaneous myocardial infarction were significantly higher after PCI than after CABG. CONCLUSIONS Among patients with multivessel coronary artery disease, the rate of major adverse cardiovascular events was higher among those who had undergone PCI with the use of everolimus-eluting stents than among those who had undergone CABG. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MASSACHUSETTS MEDICAL SOC | - |
dc.subject | LONG-TERM OUTCOMES | - |
dc.subject | GRAFT-SURGERY | - |
dc.subject | FOLLOW-UP | - |
dc.subject | INTERVENTION | - |
dc.subject | REVASCULARIZATION | - |
dc.subject | METAANALYSIS | - |
dc.subject | THROMBOSIS | - |
dc.subject | SYSTEM | - |
dc.subject | TAXUS | - |
dc.title | Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Do-Sun | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1056/NEJMoa1415447 | - |
dc.identifier.scopusid | 2-s2.0-84925427676 | - |
dc.identifier.wosid | 000351585900006 | - |
dc.identifier.bibliographicCitation | NEW ENGLAND JOURNAL OF MEDICINE, v.372, no.13, pp.1204 - 1212 | - |
dc.relation.isPartOf | NEW ENGLAND JOURNAL OF MEDICINE | - |
dc.citation.title | NEW ENGLAND JOURNAL OF MEDICINE | - |
dc.citation.volume | 372 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 1204 | - |
dc.citation.endPage | 1212 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | LONG-TERM OUTCOMES | - |
dc.subject.keywordPlus | GRAFT-SURGERY | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | INTERVENTION | - |
dc.subject.keywordPlus | REVASCULARIZATION | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | TAXUS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.